How foreign biotech firms can tap into China's latest intergovernmental R&D funding program — and why you should act before June 25, 2026.
1. The Opportunity You Might Be Missing
China's Ministry of Science and Technology (MOST) has opened the second batch of its 2026 "Intergovernmental International S&T Innovation Cooperation" Key Special Program — a government-backed initiative that funds joint R&D projects between Chinese entities and international partners.
For international IVD manufacturers, antibody developers, and biotech companies, this program offers something rare: direct Chinese government funding to co-develop products with a Chinese partner, with clear pathways to market access, regulatory navigation, and IP co-ownership.
Deadline: June 25, 2026 at 16:00 Beijing Time (UTC+8) — Online submissions via service2.most.gov.cn. Act now — the window is tight.
2. What Is This Program?
This is NOT a generic trade promotion. It's a structured bilateral R&D funding mechanism designed for genuine scientific collaboration:
- Both the Chinese side and the international side simultaneously apply to their respective government funding agencies
- Each government funds its own side of the collaboration
- Projects must demonstrate joint research goals, shared milestones, and complementary expertise
- Typical project duration: 2–3 years
- Funding per project (Chinese side): typically ¥1–3 million RMB (~$140K–$420K USD), varying by direction
The program operates across 16 distinct bilateral/multilateral directions, each targeting specific countries and research themes. For IVD and antibody companies, 5 of these directions stand out.
3. Why This Matters for International IVD & Biotech Companies
3.1 Direct Access to the World's Second-Largest IVD Market
China's IVD market exceeded ¥100 billion RMB (~$14B USD) in 2025 and continues to grow at 15–20% annually. But market entry is notoriously complex — NMPA registration, local clinical trials, and the need for a domestic legal entity often deter smaller foreign firms.
This Program Solves That
- A local sponsor for NMPA registration — provided by your Chinese partner
- Government endorsement that smooths regulatory pathways
- Shared clinical data from Chinese patient populations
- A built-in distribution network through your partner
3.2 Your R&D Gets Funded — Twice
Both sides receive government funding. Your Chinese partner's costs (personnel, equipment, clinical sites) are covered by MOST. Your own costs are covered by your national funding agency — e.g., NRF in South Korea, MBIE in New Zealand, or Horizon Europe mechanisms.
"This is essentially co-development at half the cost — with government backing on both sides."
3.3 Access to Chinese Biological Resources & Clinical Sites
China offers unique advantages for IVD and antibody R&D that are difficult to replicate elsewhere:
- Large, diverse patient populations for clinical validation
- Endemic disease samples (hantavirus, hepatitis B/C, emerging pathogens)
- Manufacturing cost advantages for recombinant antibodies and antigens
- Rapid ethics approval at major hospital networks — often 4–8 weeks vs. 6–12 months in some Western markets
3.4 IP Co-Ownership Is Standard
Unlike informal corporate partnerships, government-funded joint projects typically result in co-owned IP with clearly defined rights — including pre-agreed IP allocation templates, government oversight that prevents disputes, and commercialization rights for each party in their home market.
4. Which Directions Should You Target?
From the 16 directions in the 2026 Batch 2 program, here are the 5 most relevant for IVD, antibody, and biotech companies, ranked by fit:
🇰🇷 China–South Korea Joint Research (Direction 2.4)
| Detail | Info |
|---|---|
| Focus areas | Biotechnology; Medical & Pharmaceutical Technology |
| Funding (CN side) | ¥1–3M RMB per project |
| KR funding | Via NRF (National Research Foundation of Korea) |
| Project duration | 2–3 years |
This is the only direction that explicitly names "Biotechnology" and "Medical Technology" as focus areas. South Korea's diagnostics sector — Sugent, SD Biosensor, Boditech Med — is globally competitive and the bilateral framework is well-established.
Ideal projects: Co-development of multiplex point-of-care tests; cross-validation of antibody pairs for infectious disease panels; AI-assisted diagnostic algorithm development with shared datasets.
🇳🇿 China–New Zealand (Direction 1.1)
Focus: Health; Biomedical Research. Funding via MBIE (Ministry of Business, Innovation & Employment). NZ's agri-biotech expertise creates novel cross-sector opportunities for zoonotic disease diagnostics, biomarker discovery, and joint validation studies.
🇪🇺 China–Europe Joint Laboratory (Direction 1.2)
Focus: Health; Agricultural Food & Biotechnology. Eligible countries: UK, France, Italy, Spain, Portugal, Greece, Belgium, Norway, Netherlands, Ireland, Cyprus. This is a joint laboratory format — establishing physical presence in China — ideal for shared biobank infrastructure and recombinant antigen production platforms.
🌍 China–Arab States Joint Laboratory (Direction 1.4)
Focus: Life & Health. 17 eligible states: UAE, Saudi Arabia, Egypt, Jordan, Qatar, Kuwait, and more. Ideal for infectious disease diagnostics addressing regional endemic diseases (MERS, leishmaniasis) with China's manufacturing capabilities and your technology.
🌍 China–Africa Joint Laboratory (Direction 1.5)
Focus: Open (including Life & Health). All African nations. China's heavy investment in African healthcare infrastructure makes this a strategic market-entry pathway for point-of-care diagnostics addressing malaria, HIV, and TB.
5. How to Find a Chinese Partner
This is the #1 challenge for international applicants. Here are proven approaches:
5.1 Know Where China's Biotech Clusters Are
| Region | Specialization | Key Players |
|---|---|---|
| Shenzhen / Guangdong | IVD reagents, antibodies, diagnostic devices | Sekbio, BGI, Snibe, Wondfo |
| Shanghai / Zhangjiang | Biopharma, CRO/CDMO, molecular diagnostics | Fosun, Burnj, Hualan Bio |
| Beijing / Zhongguancun | Innovation hubs, research hospitals, AI diagnostics | CAS Institutes, Peking Union Hospital |
| Wuhan | Biological products, vaccines, diagnostics | BGI Wuhan, Wuhan Institute of Virology |
| Suzhou | Biotech parks, CDMO services | WuXi AppTec, Innovent Bio |
5.2 Where to Search
- China IVD Industry Association (CAIVD): caivd.org.cn — member directory
- MOST International Cooperation Portal: service2.most.gov.cn — list of previously funded projects
- NSFC (National Natural Science Foundation): nsfc.gov.cn — co-PI search
- LinkedIn: Search "IVD China" or "antibody manufacturer China"
- Trade shows: CMEF Shanghai (May & October), MEDICA China, AACC
5.3 Direct Outreach Tips
Practical Guidance
- Email first, then WeChat (微信): Chinese business culture moves to WeChat after initial email contact — be ready to exchange accounts.
- Bilingual proposals: Adding a Chinese summary (even AI-translated) shows effort and respect, and significantly improves response rates.
- Embassy introductions work: If your national embassy in Beijing or consulate in Shanghai can facilitate introductions, success rates increase substantially.
6. Application Timeline & Process
| Step | Deadline | Action |
|---|---|---|
| 1. Partner matching | ASAP | Identify and contact Chinese partners |
| 2. Joint proposal drafting | By June 10 | Align on project scope, milestones, and budget |
| 3. Internal review | By June 18 | Both sides review with legal teams; confirm IP terms |
| 4. Chinese side submits | June 25, 16:00 BJT | Via service2.most.gov.cn |
| 5. International side submits | Per national deadline | Via your national funding portal |
| 6. Joint review period | Jul–Sep 2026 | Both governments evaluate independently, then cross-confirm |
| 7. Results announced | Q4 2026 | Check MOST website and your national portal |
7. Common Pitfalls to Avoid
| ❌ Common Mistake | ✅ What to Do Instead |
|---|---|
| Treating this as a supplier-buyer relationship | Position as equal R&D partners — the program requires genuine scientific collaboration |
| Focusing only on product sales to China | Frame your proposal around joint technology development with measurable deliverables |
| Ignoring the bilateral submission requirement | Both sides MUST apply simultaneously — coordinate timelines carefully from day one |
| Applying with a brand-new, unknown partner | Prior collaboration history (joint papers, prior projects) significantly strengthens the application |
| Overlooking IP arrangements until late | Discuss IP ownership, licensing, and commercialization rights before drafting the proposal |
| Selecting a Chinese partner with a weak track record | MOST evaluates the Chinese entity — choose partners with relevant publications and prior government funding |
8. What Sekbio Can Offer as a Chinese Partner
Disclosure
This guide is published by Sekbio's international business development team. We are an active participant in China's government-funded collaboration ecosystem and are openly seeking international co-applicants for the 2026 program.
If you're evaluating Chinese partners for this program, Sekbio offers a combination of IVD manufacturing capability, regulatory experience, and international market reach that is rare at our scale:
- Recombinant antibody & antigen manufacturing — GMP-compliant CHO, E. coli, and Pichia expression in Shenzhen
- Established international distribution — active in Vietnam, Bangladesh, Nepal, and the Middle East
- Key product lines: Hantavirus (HTNV) diagnostic reagents, Strep A test kits, Active Blocker (heterophilic antibody blocking reagent), Ebola antibodies/antigens
- NMPA-registered products — experienced navigating China's regulatory pathway
- Prior government project experience — familiar with MOST application, budgeting, and reporting requirements
To start a conversation about co-applying for the 2026 program, contact Aimee Xie, BD Manager: aimee@sekbio.com
"China's intergovernmental S&T cooperation programs are among the most underutilized entry points for foreign biotech companies. The funding is real, the regulatory pathway is smoother, and the partner network is built-in. The deadline is June 25, 2026."
Disclaimer: This guide is for informational purposes only. Please consult the official MOST guidelines at service2.most.gov.cn and your national funding agency for authoritative application requirements.